GlassScriptPhysician profile
Alam Ali Khan
NPI 1316946288
$9,715.39
in general payments reported to CMS, 2019-2025
38 companies · $685 in 2025
The $685 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,838 · 2020: $1,594 · 2021: $1,713 · 2022: $1,093 · 2023: $1,515 · 2024: $1,277 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,257 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,257.30 |
| Education | $220.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,299.18 | 2019-2025 | |
| Novo Nordisk INC | $782.94 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $779.70 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $769.18 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $727.44 | 2019-2025 | |
| Amgen INC. | $652.60 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Janssen Pharmaceuticals, INC | $611.89 | 2019-2024 | Xarelto, Spravato |
| Napo Pharmaceuticals INC | $532.93 | 2020-2024 | Mytesi |
| Gilead Sciences, INC. | $461.06 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.83 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $326.39 | 2019-2023 | Eliquis |
| Lundbeck LLC | $309.17 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $294.62 | 2019-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $290.30 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $206.59 | 2023-2025 | Cologuard Collection Kit |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $178.10 | 2021-2023 | |
| Lilly USA, LLC | $171.92 | 2020-2025 | Mounjaro |
| Astellas Pharma US INC | $144.82 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $90.26 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.57 | 2024-2025 | Caplyta |
| Emd Serono, INC. | $78.07 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $72.02 | 2019-2024 | Dificid |
| Horizon Therapeutics Plc | $64.26 | 2020-2023 | Krystexxa |
| Xeris Pharmaceuticals, INC. | $56.46 | 2023-2024 | Gvoke Hypopen |
| Vivus LLC | $53.94 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $48.45 | 2021 | |
| Allergan, INC. | $38.19 | 2020 | |
| Mylan Specialty L.P. | $35.69 | 2022-2024 | Yupelri |
| Nestle Healthcare Nutrition INC. | $23.64 | 2021 | |
| Scilex Pharmaceuticals INC. | $22.71 | 2019 | |
| Axsome Therapeutics, INC. | $22.69 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $19.99 | 2020 | |
| Daiichi Sankyo INC. | $19.22 | 2020 | |
| Janssen Biotech, INC. | $19.05 | 2021 | |
| Lucid Diagnostics INC. | $17.36 | 2023 | |
| Bausch Health US, LLC | $15.86 | 2019 | |
| Philips North America LLC | $15.70 | 2020 | |
| Cmp Pharma, INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alam Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.